Related Experiment Video

Updated: Apr 22, 2026

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
04:55

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

Published on: May 11, 2022

4.1K

Sorting out the risks in progressive multifocal leukoencephalopathy

Leonard H Calabrese1, Eamonn Molloy2, Joseph Berger3

  • 1Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk A50, Cleveland, OH 44195, USA.

Nature Reviews. Rheumatology
|October 15, 2014
PubMed

Insights

Progressive multifocal leukoencephalopathy (PML) is a rare brain infection. This study proposes a PML risk categorization for immunosuppressive drugs to aid physician-patient decision-making regarding therapy risks and benefits.

Area of Science:

  • Neuroimmunology
  • Infectious Diseases
  • Neurology

Background:

  • Progressive multifocal leukoencephalopathy (PML) is a rare, opportunistic central nervous system infection caused by JC virus reactivation.
  • PML is often fatal and survivors frequently experience significant neurological deficits.
  • Attributing PML causality to specific immunosuppressive therapies is challenging due to confounding factors and limited understanding of pathogenesis.

Purpose of the Study:

  • To propose a categorization of immunosuppressive agents based on their associated risk of PML.
  • To support informed decision-making for physicians and patients regarding the risks and benefits of immunosuppressive therapies.

Main Methods:

  • Review and synthesis of existing literature on PML and immunosuppressive therapies.
  • Development of a risk stratification framework for immunosuppressive agents concerning PML.
  • Analysis of confounding factors and pathogenetic uncertainties.

Main Results:

  • Identification of PML as a serious complication of certain immunosuppressive treatments.
  • Establishment of a proposed categorization system for immunosuppressive drugs based on PML risk.
  • Highlighting the need for improved understanding of PML pathogenesis.

Conclusions:

  • A structured risk categorization can aid in managing PML risk associated with immunosuppressive therapies.
  • Informed decision-making is crucial for balancing the benefits of immunosuppression against the risk of PML.
  • Further research into PML pathogenesis is needed to refine risk assessment and management strategies.

More Related Videos

Mouse Models of Periventricular Leukomalacia06:24

Mouse Models of Periventricular Leukomalacia

Published on: May 18, 2010

31.4K
Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo10:50

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo

Published on: March 26, 2019

7.4K

Related Concept Videos

Encephalitis l: Introduction01:19

Encephalitis l: Introduction

Encephalitis is inflammation of the brain parenchyma, most often due to infections or autoimmune processes. It presents with neuropsychiatric features such as fever, altered mental status, behavioral changes, cognitive dysfunction, seizures, focal deficits, and sometimes autonomic instability. In some cases, the meninges are also involved, resulting in meningoencephalitis.Infectious CausesInfectious encephalitis is most commonly viral but can also result from bacterial, fungal, or parasitic...
5
Encephalitis ll: Pathophysiology01:26

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
11
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
5
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
7
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
225
Increased Intracranial Pressure ll: Pathophysiology01:29

Increased Intracranial Pressure ll: Pathophysiology

Increased intracranial pressure (ICP) refers to a potentially life-threatening rise in pressure inside the skull. This usually happens when there is a major change in the volume of brain tissue, blood, or cerebrospinal fluid (CSF) — the three components inside the skull. According to the Monro-Kellie doctrine, if the volume of one component increases, the volumes of the other components must decrease to maintain normal pressure. If this does not happen, ICP rises.The process often begins...
5